Cargando…
Olutasidenib: from bench to bedside
The discovery of isocitrate dehydrogenase 1 (IDH1) mutations in acute myeloid leukemia (AML) and the resounding success of molecularly targeted therapies in related myeloid malignancies swiftly prompted the development of IDH1(mut) inhibitors. Olutasidenib (formerly known as FT-2102) is an orally ad...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432604/ https://www.ncbi.nlm.nih.gov/pubmed/37196640 http://dx.doi.org/10.1182/bloodadvances.2023009854 |